Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma

To evaluate biological characteristics and transitions of upper tract urothelial carcinoma (UTUC) through metachronous bladder tumors after radical nephroureterectomy (RNU), we conducted immunohistochemical (IHC) staining of tumor specimens of UTUC tumor origin, non-muscle-invasive bladder cancer (NMIBC) and MIBC progressed after intravesical recurrence (IVR), and bladder primary MIBC. Fibroblast growth factor receptor 3 (FGFR3), p53, cytokeratin 5/6 (CK5/6), and CK20 were stained to examine expression rates. After expression assessment with heatmap clustering, the overexpression of four biomarkers from UTUC origin to metachronous MIBC progression was analyzed with clinicopathological variables. We found that high CK20 and low CK5/6 expression were both observed in UTUC tumor origin and subsequent NMIBC after RNU. By investigating molecular expression in the IVR specimen, we observed that low pT stage bladder recurrence occupied the majority of CK20 high CK5/6 low expression, but would change to CK20 low CK5/6 high expression as it progressed to MIBC. UTUC metachronous MIBC has different characteristics compared with bladder primary MIBC, which comprises favorable biological features such as high FGFR3 expression, and follows favorable prognosis compared to those without FGFR3 expression. The present study demonstrated that the biological characteristics of UTUC tumor origin shifts from luminal to basal-like features with progression to MIBC, but FGFR3 expression taken over from UTUC origin may comprise a favorable entity compared to primary MIBC.

[1]  E. Batourina,et al.  Pparg signaling controls bladder cancer subtype and immune exclusion , 2021, Nature Communications.

[2]  Y. Qi,et al.  Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma , 2021, The Journal of urology.

[3]  Christopher C. Griffith,et al.  Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma , 2021, PloS one.

[4]  E. Kikuchi,et al.  The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma , 2020, Cancer science.

[5]  M. Akhtar,et al.  CK20 and CK5/6 Immunohistochemical Staining of Urothelial Neoplasms: A Perspective , 2020, Advances in urology.

[6]  T. H. van der Kwast,et al.  FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†. , 2020, European urology.

[7]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[8]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[9]  M. Rubin,et al.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling , 2019, Nature Communications.

[10]  A. Lopez‐Beltran,et al.  Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype , 2019, Virchows Archiv.

[11]  B. Taylor,et al.  Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma , 2018, Clinical Cancer Research.

[12]  M. Babjuk,et al.  Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. , 2017, European urology.

[13]  Y. Okada,et al.  Recent advances in renal cell carcinoma from a pathological point of view , 2016, Pathology international.

[14]  T. H. van der Kwast,et al.  Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  N. Schultz,et al.  Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2015, European urology.

[16]  O. Cussenot,et al.  A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. , 2015, European urology.

[17]  Arndt Hartmann,et al.  Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer , 2014, Virchows Archiv.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[19]  Choung-Soo Kim,et al.  Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma. , 2013, Urologic oncology.

[20]  Y. Okada,et al.  The prognostic significance of vasohibin-1 expression in patients with prostate cancer , 2013, British Journal of Cancer.

[21]  J. Edwards,et al.  Expression and prognostic significance of Src family members in renal clear cell carcinoma , 2012, British Journal of Cancer.

[22]  K. Bensalah,et al.  The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. , 2012, European urology.

[23]  T. H. van der Kwast,et al.  The FGFR3 mutation is related to favorable pT1 bladder cancer. , 2009, The Journal of urology.

[24]  K. Bensalah,et al.  Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. H. van der Kwast,et al.  FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.

[26]  J. Cheville,et al.  Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract , 2001, Oncogene.